ClinicalTrials.govpublic full text
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
germ cell tumor, nonseminomatous germ cell tumor, seminoma, germinomatous germ cell tumor, dysgerminoma, pineal germ cell tumor, 17-160, durvalumab, tremelimumab, medi4736, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 804250
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.